Franklin Street Advisors Inc. NC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,179 shares of the company’s stock after acquiring an additional 562 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Johnson & Johnson were worth $13,271,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter worth $4,609,399,000. Providence Capital Advisors LLC increased its position in shares of Johnson & Johnson by 141,974.0% during the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after purchasing an additional 4,747,612 shares during the last quarter. Morgan Stanley raised its stake in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after buying an additional 3,849,148 shares during the last quarter. 68.40% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have commented on JNJ. Raymond James lowered their price objective on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. Credit Suisse Group increased their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Atlantic Securities boosted their target price on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. HSBC began coverage on Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective for the company. Finally, Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research report on Thursday, August 31st. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $170.65.
Johnson & Johnson Stock Performance
Shares of JNJ opened at $160.50 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The stock has a 50-day moving average price of $166.51 and a 200-day moving average price of $162.06. The company has a market cap of $417.13 billion, a PE ratio of 32.49, a price-to-earnings-growth ratio of 3.25 and a beta of 0.54. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same quarter in the prior year, the firm earned $2.59 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were given a $1.19 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s payout ratio is 96.36%.
Insiders Place Their Bets
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Reasons This Sleeping Giant Is About To Wake Up
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 9/18 – 9/22
- What is the S&P 500 and How It is Distinct from Other Indexes
- 52-week Low Names To Tip The Upside Scale In Your Favor
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
